ImmuPharma (GB:IMM) has released an update.
ImmuPharma PLC reported a reduction in its operating loss to £0.4 million for the first half of 2024, down from £0.8 million in the previous year, alongside advancements in their P140 autoimmune technology platform, including a new Phase 3 study for SLE and preparations for a Phase 2/3 study for CIDP. The company has also divested its shares in Incanthera, realizing £1.5 million and retaining significant warrants, all contributing to a strengthened financial position and continued focus on strategic partnerships and clinical progress.
For further insights into GB:IMM stock, check out TipRanks’ Stock Analysis page.
